These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38634685)

  • 41. Correlation of hepatic venous pressure gradient with variceal bleeding, size of esophageal varices, etiology, ascites and degree of liver dysfunction in cirrhosis of liver.
    Gulzar GM; Zargar SA; Jalal S; Alaie MS; Javid G; Suri PK; Shah NA; Bilal-Ul-Rehman ; Hakeem MS; Shoukat A; Dar GA
    Indian J Gastroenterol; 2009; 28(2):59-61. PubMed ID: 19696990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis.
    Ripoll C; Lastra P; Rincón D; Catalina V; Bañares R
    Scand J Gastroenterol; 2012 Feb; 47(2):204-11. PubMed ID: 22242615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy.
    Sauerbruch T; Mengel M; Dollinger M; Zipprich A; Rössle M; Panther E; Wiest R; Caca K; Hoffmeister A; Lutz H; Schoo R; Lorenzen H; Trebicka J; Appenrodt B; Schepke M; Fimmers R;
    Gastroenterology; 2015 Sep; 149(3):660-8.e1. PubMed ID: 25989386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.
    Tevethia HV; Pande A; Vijayaraghavan R; Kumar G; Sarin SK
    Gut; 2024 Oct; 73(11):1844-1853. PubMed ID: 39067870
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study.
    La Mura V; Abraldes JG; Berzigotti A; Erice E; Flores-Arroyo A; García-Pagán JC; Bosch J
    Hepatology; 2010 Jun; 51(6):2108-16. PubMed ID: 20512998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis.
    Villanueva C; López-Balaguer JM; Aracil C; Kolle L; González B; Miñana J; Soriano G; Guarner C; Balanzó J
    J Hepatol; 2004 May; 40(5):757-65. PubMed ID: 15094222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.
    Bossen L; Krag A; Vilstrup H; Watson H; Jepsen P
    Hepatology; 2016 Jun; 63(6):1968-76. PubMed ID: 26599983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preventing first variceal hemorrhage in cirrhosis.
    Albillos A
    J Clin Gastroenterol; 2007; 41 Suppl 3():S305-11. PubMed ID: 17975481
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension.
    Semmler G; Simbrunner B; Scheiner B; Schwabl P; Paternostro R; Bucsics T; Stättermayer AF; Bauer D; Pinter M; Ferenci P; Trauner M; Mandorfer M; Reiberger T
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2164-2172. PubMed ID: 31062417
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.
    Schwarzer R; Kivaranovic D; Paternostro R; Mandorfer M; Reiberger T; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1162-1169. PubMed ID: 29492989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis.
    Merkel C; Bolognesi M; Sacerdoti D; Bombonato G; Bellini B; Bighin R; Gatta A
    Hepatology; 2000 Nov; 32(5):930-4. PubMed ID: 11050041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
    La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
    J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension.
    Lisotti A; Azzaroli F; Cucchetti A; Buonfiglioli F; Cecinato P; Calvanese C; Simoni P; Arena R; Montagnani M; Golfieri R; Colecchia A; Festi D; Mazzella G
    Liver Int; 2016 Sep; 36(9):1313-21. PubMed ID: 26786880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beta-blockers in the era of precision medicine in patients with cirrhosis.
    Albillos A; Krag A
    J Hepatol; 2023 Apr; 78(4):866-872. PubMed ID: 36529293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg.
    Jindal A; Bhardwaj A; Kumar G; Sarin SK
    Am J Gastroenterol; 2020 Oct; 115(10):1624-1633. PubMed ID: 32453061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adipopenia correlates with higher portal pressure in patients with cirrhosis.
    Rodrigues SG; Brabandt B; Stirnimann G; Maurer MH; Berzigotti A
    Liver Int; 2019 Sep; 39(9):1672-1681. PubMed ID: 31207018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Nonselective β-Blockers on Mortality in Patients With End-Stage Cirrhosis.
    Snoga JL; Lusk KA; Attridge RT; Attridge RL
    Ann Pharmacother; 2020 Apr; 54(4):322-330. PubMed ID: 31701773
    [No Abstract]   [Full Text] [Related]  

  • 58. The risk factors for bleeding of fundal varices in patients with liver cirrhosis.
    Park EJ; Jang JY; Lee JE; Jeong SW; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Cho JY; Kim HS; Kim BS; Kim YJ
    Gut Liver; 2013 Nov; 7(6):704-11. PubMed ID: 24312712
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
    Kim SG; Kim TY; Sohn JH; Um SH; Seo YS; Baik SK; Kim MY; Jang JY; Jeong SW; Lee B; Kim YS; Suk KT; Kim DJ
    Am J Gastroenterol; 2016 Nov; 111(11):1582-1590. PubMed ID: 27575713
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis.
    Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Balcar L; Hofer B; Pfisterer N; Schwarz M; Scheiner B; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2318-2326.e7. PubMed ID: 35842118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.